Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)

Exclusion Criteria

• •1. Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome)；
• •2. Individuals with ≥ 3 cardiovascular risk factors (male\>55 years old, female\>65 years old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol/L and/or impaired fasting glucose (6.1-6.9mmol/L); LDL-C ≥ 3.4mmol/L (130mg/dl), HDL-C\<1.0mmol/L (40mg/dl) or TC ≥ 5.2mmol/L (200mg/dl); Family history of early onset of cardiovascular disease, age of onset of first degree relatives\<50 years old; Abdominal obesity, waist circumference: male\>90cm, female\>85cm or BMI\>28kg/m2) or hypertensive target organ damage;
• •3. riser hypertension (defined as night blood pressure higher than daytime blood pressure by ABPM)
• •4. Regular night shift workers
• •5. Individuals taking other medications that may affect blood pressure (such as glucocorticoids);
• •6. Individual with history of kidney or kidney surrounding tissue surgery;
• •7. Individuals with impairment of liver or kidney function (ALT, AST or creatinine greater than 2 times of the upper limit of normal reference);
• •8. Individual with myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment;
• •9. Individual with type 1 diabetes or uncontrolled type 2 diabetes；
• •10. Individual with uncontrolled thyroid dysfunction;
• •11. Individual with urinary calculi or hematuria；
• •12. Individual with atrial fibrillation;
• •13. Individual with severe structural heart disease (e.g. valvular heart disease, cardiomyopathy, congenital heart disease);
• •14. Individual with second degree and above atrioventricular block and/or sick sinus syndrome;
• •15. Individual with abnormal coagulation function;
• •16. Individual with infected waist skin;
• •17. Individual with claustrophobia；
• •18. Individual with malignant tumor;
• •19. History of allergy to amlodipine, olmesartan, and hydrochlorothiazide
• •20. Individual is pregnant, nursing or planning to be pregnant;
• •21. Individual is unwilling to sign informed consent;
• •22. Individual fails to complete the screening period.